Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | SELISARC: selinexor plus gemcitabine in leiomyosarcoma and osteosarcoma

Javier Martin Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, discusses findings from the Phase I SELISARC trial (NCT04595994), which studied selinexor plus gemcitabine. This combination was shown to be synergistic in pre-clinical models in other cancers. In certain sarcoma subtype models, selinexor was shown to be active. The aim of this trial was to find the recommended Phase II dose for future study. For patients with leiomyosarcoma, there was a benefit in terms of progression-free survival (PFS). However, in patients with osteosarcoma, there was no signals of activity, as seen in preclinical data. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.